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Gastrointestinal stromal tumors (GISTs) are themajor gastrointestinalmesenchymal tumorswith a variablemalignancy
ranging froma curable disorder to highlymalignant sarcomas.Metastasis and recurrence are themain causes of death
in GIST patients. To further explore the mechanism of metastasis and to more accurately estimate the recurrence risk
of GISTs after surgery, the clinical significance and functional role of collagen triple helix repeat containing-1 (CTHRC1)
in GIST were investigated. We found that CTHRC1 expression was gradually elevated as the risk grade of NIH
classification increased, and was closely correlated with disease-free survival and overall survival in 412 GIST patients.
In vitro experiments showed that recombinant CTHRC1 protein promoted the migration and invasion capacities of
primary GIST cells. A luciferase reporter assay and pull down assay demonstrated that recombinant CTHRC1 protein
activated noncanonical Wnt/PCP-Rho signaling but inhibited canonical Wnt signaling. The pro-motility effect of
CTHRC1 on GIST cells was reversed by using a Wnt5a neutralizing antibody and inhibitors of Rac1 or ROCK. Taken
together, these data indicate that CTHRC1 may serve as a new predictor of recurrence risk and prognosis in post-
operative GIST patients and may play an important role in facilitating GIST progression. Furthermore, CTHRC1
promotes GIST cell migration and invasion by activating Wnt/PCP-Rho signaling, suggesting that the CTHRC1-Wnt/
PCP-Rho axis may be a new therapeutic target for interventions against GIST invasion and metastasis.
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Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms
that usually arise in the stomach or small intestine and typically cause
bleeding, anaemia and pain [1]. It is believed that GISTs originate from
interstitial cells of Cajal [2] and may also derive from gastrointestinal
smoothmuscles or gut stem cells [3]. The pathological features ofGISTs
range from benign neoplasms to fatal sarcomas [1,4]. Most
gastrointestinal stromal tumors stain positively for KIT [5,6], Ki67
[7] and anoctamin 1; exon mutations [6] in KIT or PDGFRA genes in
approximately 80% or 10% of GISTs, respectively, have been
demonstrated [1]. More than 60% of GIST patients can be cured by
surgical resection [8,9]. The use of imatinib mesylate (Gleevec;
Novartis) adjuvant treatment [8] is recommended in advanced GIST
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improved; however, secondary imatinib resistance is common [10].
Micrometastases and overt metastases are the main causes of death in
malignant tumors, and this is the case in GIST patients as well [11,12].
Approximately 40% GISTs patients had metastatic lesions when
definitively diagnosed, and more than 10% patients exhibited overt
metastases [1]. Therefore, developing new predictors that can be used to
estimate the risk of metastasis and postoperative recurrence is urgent.
Extracellular matrix (ECM) proteins play important roles in
regulating tumor invasion and metastasis [13-15]. Given the secretary
property, ECM proteins are also ideal candidates for tumor serum
biomarkers and therapeutic targets.
Collagen triple helix repeat containing-1(CTHRC1) is a 28-kD
extracellular matrix glycoprotein containing an NH2-terminal
signaling peptide for extracellular secretion, a short collagen triple
helix repeat of 36 amino acids, and a COOH-terminal globular
domain [16].CTHRC1 was initially found in a screen for differentially
expressed genes in balloon-injured versus normal rat arteries [16]. It
has been reported that the CTHRC1 protein positively regulates the
Wnt-PCP pathway by stabilizing formation of the Wnt ligand and
Frizzled receptor complex [17] in developmental morphogenesis [17].
CTHRC1 has recently been shown to be highly expressed in human
pancreatic cancer tissues [18], hepatocellular carcinoma [13], gastric
cancer [19], and colorectal cancer [20], and it promotes invasion and
metastasis in these cancers. Several studies revealed that CTHRC1
regulates cancer cell motility and invasiveness through activating the
Wnt-PCP pathway [18]. However, the clinical significance and
functional role of CTHRC1 in GIST remain unclear. In this study,
we first examined the expression of CTHRC1 and its correlation with
the clinicopathological parameters of GIST. Then, we further
analyzed the relationship between CTHRC1 expression and the
survival of GISTs patients and identified CTHRC1 as a novel
prognostic factor of GIST. Finally, we demonstrated that CTHRC1
promoted migration and invasion of primary GIST cells through
activated Wnt/PCP-Rho signaling.Materials and Methods
Ethics Statement
We obtained approval from the Regional Ethical Committees,
Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
Shanghai, China for the use of clinical GIST patients' tissues. All the
patients joined this study have signed informed consent. Ethical
approval number, 2012031.
Patients
The inclusion criteria for our study were as follows: 1) a distinct
pathologic diagnosis of GIST (CD117 positive in immunohisto-
chemistry staining) ; 2) primary GIST cases without history of other
solid tumors; 3) accepted radical surgery treatment without tumor
residual; 4) without any chemotherapy, radiotherapy or other anti-
cancer therapies before surgery; 5) availability of complete clinico-
pathologic and follow-up data; 6) obtained informed consent of
patients and approval of the ethics committee of Renji Hospital for
the use of samples. A total of 412 GIST cases, pathologic diagnosed
and treated range from September 2004 to September 2013, were
retrospectively identified from the hospitalization archives of
Department of General Surgery, Renji Hospital, Shanghai, China.
The paraffin-embedded tissue samples of these patients were used fortissue microarray construction and immunohistochemical staining.
The clinicopathologic parameters include patients' age, gender,
pathogenic site, histological type, tumor size (cm), number of
mitoses/50 high-power fields (HPF), tumor rupture, mutation type
and imatinib adjuvant treatment regimens. The risk of GIST behavior
was classified into very low, low, intermediate, and high-risk
categories according to the modified National Institute of Health
(NIH) consensus [21,22]. In our study, the criterion of imatinib
adjuvant therapy is at least twelve months uninterrupted drugs at a
dose of 400mg/day. All the patients involved in our research accepted
physical examination once a month during the first year after surgery
and every six months thereafter. High risk GIST patients were
accepted computed tomography (CT) or magnetic resonance imaging
(MRI) of abdomen and pelvis at three-months intervals during the
first three years after surgery, and subsequently at six-months intervals
until five years after surgery. Complete follow-up data for GIST
patients in cohort were available. Patients were followed until
September 2013. Overall survival (OS) was defined as the time from
surgery to death or the last follow-up examination. Disease free
survival (DFS) was defined from the date of surgery until the
detection of tumor recurrence or last observation.
Tissue Microarray Construction
Tissue microarrays were constructed by Suzhou Xinxin Biotech-
nology ( Xinxin Biotechnology Co, Suzhou, China). Tissue paraffin
blocks of GIST samples were stained with hematoxylin-eosin to
confirm the diagnoses and marked at fixed points with most typical
histological characteristics under a microscope. Two 1.6 mm cores per
donor block were transferred into a recipient block tissue
microarrayer, and each dot array contained fewer than one hundred
and sixty dots. Three-micron-thick sections were cut from the
recipient block and transferred onto glass slides using an adhesive tape
transfer system for ultraviolet cross linkage.
Immunohistochemistry Stain
The tissue microarray glass slides were baked at 55°C for one hour,
and then de-paraffinized gradually through xylene, 50% xylene, gradient
concentrations of ethanol until immersed in tap water. Tissue sections
were blocked for peroxidase activity with 0.3% Hydrogen peroxide at
37°C for 30mins. Antigen retrieval was carried out via boiling in
10mmol/L citrate buffer (pH6.0) for fifteen mins. Then the tissues were
incubated withCTHRC1 antibody (mouse monoclonal antibody, 1:100
dilution, Huaan Biotechnology, Hangzhou, China) overnight at 4°C.
Next day, the tissues were washed with phosphate buffer solution (PBS)
for three times and incubated with HRP-labelled anti-mouse secondary
antibody (1:200dilution, Dako, Carpinteria , CA, USA) for one hour at
room temperature. Immunostaining was carried out using diaminoben-
zidine substrate chromogen (Dako, Carpinteria, CA, USA) method and
chromogenic reaction was controlled under microscope. After immu-
nostaining, tissues were immersed into hematoxylin for nuclear staining.
The TMA slides were then dehydrated through gradient concentrations
of ethanol, cleared with xylene, and coverslipped with neutral balsam
(Shenggong , Shanghai, China). The staining results were judged by two
pathologists according to criterion as follows: 0: weak, no staining was
observed; 1+, 25% to 50% of the tumor cells were weak or moderate
staining; 2+, strong,more than 50% tumor cells weremoderate or strong
staining. 1+ and 2+ scores were identified as positive staining, while
0 score means negative staining. Negative controls for primary and
secondary antibodies were shown in Figure W3. Total RNA Extraction
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GIST tissues using Trizol reagent (Takara, Dalian, China) followed the
manufacturer instructions. The reverse-transcription reactions were
carried out with random primers and M-MLV Reverse Transcriptase
(Takara, Dalian, China). The 29 cases of cDNAwere used for templates
of quantitative real-time PCR reaction in SYBR-Green method. All the
qPCR reactions were performed on a StepOneTM real-time PCR System
(Applied Biosystems, Foster City, CA,USA). Beta-actin was used as an
internal control. The 2-△Ct method was used to quantify the relative
CTHRC1 expression levels. The forward and reverse CTHRC1 primer
sequences were: 5′-TGGTATTTCACATTCAATGGAGCTG-3′ and
5′-TGGGTA- -ATCTGAACAAGTGCCAAC-3′, respectively.
Western Blotting
Fresh GIST tissues were lysed in tissue protein extraction reagent
(Invitrogen). Primary GIST cells were lysed in Western and IP lysis
buffer (P0013, Beyotime, Jiangsu, China) supplemented with 1mM
PMSF (Adamas beta, Shanghai, China). The lysis buffer includes,
20mM Tris (pH7.5), 150mM NaCl, 1%Triton X-100, sodium
pyrophosphate, β-glycerophosphate, EDTA, Na3VO4, leupeptin.Figure 1. CTHRC1 expression in GIST tissues. (A) Relative mRNA ex
those in the intermediate- and high-risk groups. (B) Western blotting a
was significantly higher than those of low-risk or intermediate-risk gro
image of immunohistochemical staining of CTHRC1 in low-risk, interm
100×; d, e, f, 200×. Scale bars, 5 μm (*, P b 0.05).Proteins were separated by 10% SDS-PAGE under reducing con-
dition, followed by blocking in phosphate-buffered saline/Tween-20
containing 1%BSA (Bovine Serum Albumin). The NC (Nitrocellu-
lose filter membrane) or PVDF (Polyvinylidenefluoride) membrane
was incubated with antibodies for CTHRC1(1:1000, mouse, Huaan,
Hangzhou, China) , JNK (1:1000, Rabbit source, Cell Signaling
Technology), RhoA (1:1000,Rabbit,CST), Rac1(1:1000,Mouse,
Millipore) ,Cdc42 (1:1000,Mouse) and species-specific secondary
antibodies. Bound the IRDye 680 anti-mouse (LI-COR, 1:20000)
and IRDye 800 anti-rabbit (LI-COR, 1:10000) secondary antibodies
were revealed by Odyssey imaging system (LI-COR). Wnt5a
neutralizing antibody (R&D), Wnt3a neutralizing antibody
(R&D), NSC23766 (Rac1 inhibitor, Merck Millipore, effective
dose: 50 μM), Y-27632 (ROCK inhibitor, effective dose: 100 μM).
CTHRC1 Recombinant Protein Expression, Purification
and Verification
CTHRC1 ORF were cloned into the episomal expression vector
V152 (Figure W1B) with pCEP-Pu-Strep II-tag (C-terminal) in-
frame and the sequence of the BM-40 (SPARC/osteonectin) signalpression of CTHRC1 in low-risk group was significantly lower than
nalysis showed that CTHRC1 expression in high-risk GIST patients
ups. Tubulin was included as a loading control. (C) Representative
ediate-risk and high-risk GIST tissues. Original magnification: a, b, c,
Table 1. Relationship between CTHRC1 expression and clinicopathologic features of GIST
patients( *, P b 0.05; **, P b 0.01).
Variable CTHRC1(n = 412)
Low High P
Age $ ≤59 years 31 49 0.458
N59 years 114 218
Gender Male 65 158 0.005
Female 80 109
Tumor site Stomach 100 128 b0.001
Small bowel 28 93
Colon 12 9
Other sites 5 37
Tumor size(cm) ≤2 30 7 b0.001
N2&≤5 102 61
N5&≤10 9 127
N10 4 72
Mitoses per 50 HPFs ≤5 138 170 b0.001
N5&≤10 2 52
N10 5 45
Modified NIH criteria Very low risk 30 2 b0.001
Low risk 101 51
Intermediate risk 4 58
High risk 10 156
NIH invasion 1 30 2 b0.001
2 101 51
3 4 58
4 5 101
5 5 55
Tumor bleeding No 131 220 0.030
Yes 14 47
Abbreviations: HPF, high power field of the microscope; NIH, National Institutes of Health.
The P value in bold emphasize statistical significance (Pb0.001).
$ Median age of total 412 patients was 59 years.
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recombinant expressed in EBNA-293 cells after transfecting
reconstructed plasmid by using X-tremeGENE 9 DNA Transfecting
Reagent (Roche, Mannheim, Germany). Forty eight hours after
transfection, the EBNA-293 cells were screening with puromycin
(Sigma-Aldrich, St. Louis, MO) at a dose of 2μg/ml in DMEM
supplemented with 10% FBS for seven days, then the culture media
were collected and applied to the Strep Tactin sepharose column(IBA,
Gottingen, Germany). After this, the column was washed with
binding buffer and eluted by elution buffer containing 2.5 mM
desthiobiotin. The collected fractions were further quantified by
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE) and BCA Protein Assay Kit (Pierce. Biotechnology
Inc, Rockford, IL) and identified by western blotting assay.
In Vitro Migration and Invasion Assays
For the transwell migration assay, 4×104 primary GIST cells were
placed on the top chamber of each insert with the noncoated
membrane (Millicell). Cells were trypsinized and resuspended in
DMEM and 700-900μL of medium supplemented with 10% fetal
bovine serum added rCTHRC1 protein followed gradient doses of
0 nM, 1 nM, 20 nM, 50 nM respectively were injected into the lower
chamber. After 24 hours for GIST cells in the migration assays, any
cells remaining in the top chambers or on the upper membrane of the
inserts were carefully removed. After fixation and staining in a dye
solution containing 0.1% crystal violet and 20% methanol, cells
adhering to the lower membrane of the inserts were counted and
imaged through an IX71 inverted microscope (Olympus Corp.
Tokyo, Japan). We carried out invasion assay by adding 100μl
matrigel (BD Bioscience, Franklin Lakes, NJ) into top chamber of
transwell and placed 8×104 primary GIST cells onto the matrigel. 48
hours later, the transwell for invasion was ceased and staining.
Cell Viability Assay
Cell viability was detected using a standardCell CountingKit-8 assay.
Primary GIST cells were seeded into 96-well plates (100μl per well) at a
density of 3×104 cells per ml. Cells in four divided groups were added
rCTHRC1 protein followed gradient doses of 0 nM, 1 nM, 20 nM,
50 nM respectively. We added 10μl of reagent from Cell Counting
Kit-8 (Dojindo, Kumamoto, Japan) to each well for detection at day
1, 2, 3, 4, 5. After two hours of incubation at 37°C, the optical density
was measured using microplate reader at a wavelength of 450nm.
Cell Isolation and Primary Cell Culture
Fresh surgical GIST tissues were gently minced with scissors,
washed twice with phosphate-buffered saline (PBS), and then filtered
through the steel mesh with 200 μm pore diameter. After washed in
cold PBS, cell pellets were resuspended in RPMI-1640 medium
supplemented with 20% fetal calf serum (FCS; Gibco, France) and
seeded onto culture dishes. The primary GIST cells were cultured in
incubator with 5%CO2 and 37 degrees centigrade. The culture
medium for primary GIST cells were changed twice every three days .
The successfully isolated primary GIST cells were shown in Figure 3A.
Pull Down Assay
Pull down assays were conducted as reported [23] . Primary GSIT
cells cultured in 100 mm dishes were serum-starved for 24 hours and
treated with rCTHRC1 at a dose of 20 nM or desthiobiotin buffer for
2 hours. The primary antibodies used included the following: mouseprimary antibody against Rac1 (Millipore, 1:1000) and rabbit primary
antibody against RhoA, Cdc42 (Cell Signaling Technology, 1:1000).
Luciferase Reporter Assay
Primary GIST cells were seeded in 96-well plates and transfected
with mixture of 100 ng TCF/catenin reporter plasmid (Wnt/β-
catenin signaling), or 100 ng ATF2 reporter plasmid (Wnt/PCP
signaling), and 10 ng Renilla following the recommended protocol for
the Lipofectamine 2000 transfection system. One group of GIST cells
were treated with rCTHRC1 protein at a concentration of 20 nM.
After 48 hours of incubation, firefly and Renilla luciferase activities
were measured using the dual-luciferase reporter assay system
(Promega, Madison, WI) from the cell lysates.
Statistical Analysis
Statistical analyses were conducted using SPSS 16.0 software
(Chicago, IL, USA). We performed chi-squared tests in cross tables to
assess the relationships between expression levels of CTHRC1 and
clinicopathological factors. Overall survival (OS) and Disease-free
survival (DFS) were calculated using Kaplan-Meier method. The
survival distributions were compared through log-rank test. All
statistical tests were two-sided. One-way analysis of variance
(ANOVA, Post-hoc testing) was used to compare groups
(TableW1). P value less than 0.05 was considered statistically significant.
Results
CTHRC1 Expression Is Gradually Elevated in Accordance
with GIST Risk Grades
To investigate the CTHRC1 expression level in GIST tumor
tissues with different risk grades, we first evaluated the mRNA
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quantitative PCR (qPCR). The results showed that CTHRC1mRNA
expression levels in GIST tumor tissues of the intermediate- and high-
risk groups were higher than those of the low-risk group (Figure 1A).
We further compared the protein expression level of CTHRC1 in
GIST tissues with different risk grades. The three low-risk, two
intermediate-risk and five high-risk samples were analyzed by western
blotting. The results showed that the CTHRC1 protein expression
level in the high-risk group was significantly higher than that of the
intermediate- and low-risk groups (Figure 1B).
CTHRC1 Protein Expression Level Is Closely Correlated with
Risk Grade of NIH Classification, and Prognosis of GIST
The clinicopathological significance of CTHRC1 was further
examined using a tissue microarray which contained 412 GIST
tissue samples. The immunohistochemistry staining results showed
that 145 (35.2%) cases showed CTHRC1 low expression, 267
(64.8%) cases showed CTHRC1 high expression (Figure 1C). The
correlations between CTHRC1 expression and the clinicopatho-
logical parameters are shown in Table 1. We found that the
expression level of CTHRC1 was higher in the patients with high
NIH grade, large tumor size (N10 cm) or increased mitotic figuresFigure 2. (A) Kaplan-Meier analysis of overall survival related to the ex
of disease-free survival related to the expression of CTHRC1 in 412 G
risk GIST patients, there was no significant difference in DFS between
CTHRC1-positive intermediate- and high-risk GIST patients, no sign
surgery alone group were observed.than those with low NIH grade, small tumor size (b10 cm), fewer
mitotic figures with statistical significance (P b 0.05). Interestingly,
we found that there was a significant difference between male
(70.85%) and female (57.67%) GIST patients in frequency of high
CTHRC1 levels. The statistical analysis suggested that CTHRC1
expression was not correlated with age, histological type, or tumor
rupture. We further investigated the correlation between CTHRC1
expression and overall survival (OS) or disease-free survival (DFS)
of GIST patients. The OS in the CTHRC1 negative (low) group
(five-year OS rates, 100%, 145/145) was remarkably superior than
that in the CTHRC1 positive (high) expression group (five-year
OS rates, 90.6%, 242/267) (Figure 2A). The DFS in the CTHRC1
negative (low) group (five-year DFS rates, 95.2%, 138/145) was
significantly higher than that in the CTHRC1 positive (high)
expression group (five-year DFS rates, 76.8%, 205/267)
(Figure 2B). In summary, CTHRC1 expression in GIST tumor
tissues was closely correlated with OS and DFS of GIST patients.
Correlation between CTHRC1 Expression and the Efficacy of
Imatinib Adjuvant Treatment
According to the NIH classification guideline, intermediate- or
high-risk GIST patients require adjuvant treatment with imatinib. Inpression of CTHRC1 in 412 GIST patients. (B) Kaplan-Meier analysis
IST patients. (C) Among CTHRC1-negative intermediate- and high-
the groups with or without imatinib adjuvant treatment. (D) Among
ificant difference between the imatinib treatment group and the
Figure 3. (A) Immunofluorescent staining showed the morphology of primary GIST cells isolated from the GIST tissues of three patients.
The green fluorescence represents phalloidin for F-actin staining, whereas the blue fluorescence represents DAPI for nuclear staining.
(B) Cell viability of primary GIST cells treatedwith rCTHRC1 protein at doses of 0 nM, 1 nM, 20 nM, 50 nMweremeasured using CCK-8 assay
for six days. (C) Representative images (left) of GIST cells that migrated to the bottom of transwell filter (8μm, pore diameter) and statistical
analysis (right) of the cell migration stimulated with rCTHRC1 protein or vehicle. (D) Representative images (left) of GIST cells that invaded
through Matrigel to the bottom of transwell filter (8μm, pore diameter) and statistical analysis (right) of the cell invasiveness stimulated with
rCTHRC1 protein or vehicle. The results shown are mean±SD of migration, and invading cells were photographed at 200× magnification
per field. (*, P b 0.05; **, P b 0.01).
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imatinib adjuvant treatment and CTHRC1 expression. Among 14
CTHRC1- negative intermediate- and high-risk GIST patients, there
was no correlation between imatinib treatment and patient prognosis
(Figure 2C). The difference in DFS between the imatinib treatment
group and the surgery treatment only group was not statistically
significant (P = 0.255). Notably, among 214 CTHRC1- positiveFigure 4. (A) Dual-luciferase reporter assay showed that rCthrc protei
dependent manner. The results shown are mean±SD of relative firefly
activated by rCTHRC1 protein in a dose-dependent manner. (C) The in
blocked by Wnt5a monoclonal neutralizing antibody. (D) The promo
blocked by Wnt5a monoclonal neutralizing antibody. (E) The promoti
by Wnt3a monoclonal neutralizing antibody. (F) The promoting effec
monoclonal neutralizing antibody. (*, P b 0.05; **, P b 0.01).intermediate- and high-risk GIST patients, the DFS rate in the
imatinib treatment group were higher than that in the surgery
only group within 3 years of follow-up. However, the differences in
5-year DFS rates in the two groups were not statistically significant
(P = 0.313) (Figure 2D). Therefore, the expression of CTHRC1
can not predict the efficacy of imatinib adjuvant treatment in our
current study.n inhibited Wnt/β-catenin signaling of primary GIST cells in a dose-
/Renilla ratio. (B) Noncanonical Wnt/PCP signaling of GIST cells was
hibitory effect of rCTHRC1 on Wnt/β-catenin signaling was partially
ting effect of rCTHRC1 protein on Wnt/PCP signaling was almost
ng effect of Wnt3a on Wnt/β-catenin signaling was almost blocked
t of Wnt5a on Wnt/PCP signaling was almost blocked by Wnt5a
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and Invasion in a Dose-dependent Manner
To explore the biological functions of CTHRC1 as a secreted
protein, CTHRC1 was recombinantly expressed in EBNA-293
cells, and further purified and verified by western blotting (FigureW2).
Then, the purified recombinant CTHRC1 (rCTHRC1) protein
was applied to primary GIST cells in a migration and Matrigel
invasion assay. Compared to the vehicle group, GIST cell migration
and invasion were significantly enhanced by rCTHRC1 protein at
doses of 1 nM, 20 nM, and 50 nM (Figure 3, C and D). Moreover,
the promotion of cell motility by the rCTHRC1 protein was
dose-dependent. However, primary cell viability was not remarkably
affected by rCTHRC1 protein based on the cell viability assay
(Figure 3B). These results demonstrate that CTHRC1 is a
potent pro-invasion factor that facilitates GIST cell invasion in a
dose-dependent manner.Figure 5. (A) Analysis of the active and total RhoA,Rac1 and Cdc42
assay.(B) Quantitative analysis of grey value for active Rac1/ -total R
value for active RhoA/ -total RhoA ratio using ImageJ software. (D)
ratio using ImageJ software. (E) Rac1 G-LISA assay was used to
rCTHRC1 protein. (F) RhoA G-LISA assay was used to assess the
protein. (*, P b 0.05; **, P b 0.01).CTHRC1 Activates Wnt/PCP-Rho Signaling in Primary
GIST Cells
To understand the underlying mechanism by which CTHRC1
promotesGIST cell migration and invasion, we examined the activation
of the canonical Wnt pathway and the non-canonical Wnt pathway.
GIST cells were transfected with a Wnt//β-catenin reporter plasmid
(TCF/catenin plasmid) and negative control counterpart plasmid or
non-canonical Wnt/PCP pathway reporter plasmid (ATF2 plasmid).
Recombinant CTHRC1 or vehicle control was added 24 hours after
transfection, and luciferase activity was determined. The results showed
that Wnt/β-catenin signaling was inhibited while the noncanonical
Wnt/PCP signaling was activated by rCTHRC1 protein in primary
GIST cells (Figure 4, A and B). The effects of rCTHRC1 protein on
Wnt signaling was blocked by aWnt5a neutralizing antibody (Figure 4,
C and D). We also verified the block effect of Wnt3a and Wnt5a
neutralizing antibodies (Figure 4, E and F). We further confirmed thein primary GIST cells treated with rCTHRC1 protein by pull-down
ac1 ratio using ImageJ software. (C) Quantitative analysis of grey
Quantitative analysis of grey value for active Cdc42/ total Cdc42
assess the levels of GTP-bound Rac1 in GIST cells treated with
levels of GTP-bound RhoA in GIST cells treated with rCTHRC1
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western blotting assy. The level of phosphorylated β-catenin, which
indicates the degradation of β-catenin, was increased in primary GIST
cells treated with rCTHRC1 (Figure 6, B and F). In addition, the level
of GSK3β, which phosphorylates β-catenin on Ser-33/Ser-37/Thr-41
was increased in rCTHRC1 treated primary GIST cells (Figure 6, B
andD). Therefore, we confirmed that CTHRC1 inhibits the canonical
Wnt/β-catenin pathway in primary GIST cells.
The downstream molecules of the Wnt/PCP pathway mainly
include the small GTPase family, such as Rac1, RhoA and Cdc42,
which play important roles in cancer cell migration and invasion.
Using a Rho GTPases pull-down assay, we found that the rCTHRC1
protein enhanced the activity of RhoA and Rac1 but not Cdc42
(Figure 5, A-D).
To further confirm the above results, the GLISA assay, another
approach to measure the activities of Rho GTPases, was performed. It
also demonstrated that the activities of RhoA and Rac1 wereFigure 6. (A) The expression of Wnt5a and the phosphorylation of
blotting. (B) The phosphorylation of GSK3β and β-catenin were
(C) Quantitative analysis of grey value for Wnt5a using ImageJ so
at 0′, 5′, 10′, 30′ was compared with the grey value of Wnt5a ind
for phospho-GSK3β/total GSK3β ratio using ImageJ software. (E)
ratio using ImageJ software. (F) Quantitative analysis of grey
software. (*, P b 0.05; **, P b 0.01).significantly enhanced by rCTHRC1 treatment in primary GIST cells,
which is consistent with the results of the Rho GTPases pull-down
assay (Figure 5, E and F).
Furthermore, the phosphorylation of c-Jun N terminal kinase
(JNK), another downstream molecule of the Wnt/PCP pathway, and
Wnt5a were also elevated by rCTHRC1 treatment (Figure 6, A, C
and E). These results suggested that CTHRC1 may promote GIST
cell invasion through the Wnt/PCP-Rho-JNK pathway.
CTHRC1-induced Primary GIST Cell Migration and
Invasion Is Wnt5a and Wnt/PCP Signaling-dependent
We further investigated whether Wnt3a (a ligand of canonical
Wnt/β-catenin pathway) and Wnt5a (a ligand of noncanonical
Wnt/PCP pathway) are involved in CTHRC1-induced GIST cell
migration and invasion by using neutralizing antibodies of Wnt3a
and Wnt5a. The data illustrated that the migration- and invasion-
promoting activities of rCTHRC1 at a dose of 20 nM were notJNK were examined after treatment with rCTHRC1 by western
examined after treatment with rCTHRC1 by western blotting.
ftware. The relative expression of Wnt5a induced by rCTHRC1
uced by rCTHRC1 at 60′. (D) Quantitative analysis of grey value
Quantitative analysis of grey value for phospho-JNK/total JNK
value for phospho-β-catenin/totalβ-catenin ratio using ImageJ
Figure 7. (A) The promotive effect of rCTHRC1 protein was blocked byWnt5a neutralizing antibody but not blocked byWnt3a neutralizing
antibody shown from cell migration assay in vitro. (B) Quantification analysis of migrated cells were performed for six randomly selected
fields (original magnification:200×). (C) The promotive effect of rCTHRC1 protein was partially blocked by Rac1 inhibitor (NSC23766) as
well as ROCK inhibitor (Y-27632) shown from cell migration assay. (D) Quantification analysis of migrated cells were performed for six
randomly selected fields (original magnification:200×). (*, P b 0.05; **, P b 0.01).
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Figure 8, A and B). However, the promoting effects of rCTHRC1
on GIST cell migration and invasion were almost completely
blocked by the Wnt5a neutralizing antibody (Figure 7, A and B,
Figure 8, A and B). We further investigated whether the promoting
effects of CTHRC1 on GIST cells motility are Wnt/PCP signaling-
dependent by using inhibitors of ROCK and Rac1, which are key
downstream molecules of the Wnt/PCP pathway. The results
showed that both ROCK and Rac1 inhibitors treatment inhibits the
promoting effects of rCTHRC1 on GIST cell migration and
invasion (Figure 7, C and D, Figure 8, C and D).
Taken together, these data indicated that the CTHRC1-induced
GIST cell migration and invasion isWnt5a and noncanonicalWnt/PCP
signaling dependent (Figure 9).
Discussion
GISTs have a variable malignancy degree ranging from a curable
disorder to highly malignant sarcomas [1,8]. The majority of GISTs
stain positive for KIT oncoproteins in immunohistochemical assays[3,24]. KIT is a stem cell growth factor receptor that plays pro-
proliferative and anti-apoptotic roles in GIST progression [5,6].
GIST patients treated with the KIT targeted inhibitor, − imatinib,
showed prolonged median recurrence-free survival of 12 to 24
months [1,21]. Recurrence and metastasis in GIST patients are the
major causes of treatment failure or even death [7,25,26]. Thus, new
predictive biomarkers for recurrence and an understanding of the
mechanisms of GIST metastasis are urgently needed.
By analyzing the GIST microarray dataset (GSE21315) from the
GEO database (Figure W1A), we found that CTHRC1 expression in
GIST with liver metastasis was remarkably higher than in primary
GIST tissues(fold changeN3, P b 0.05). This result strongly suggested
that CTHRC1 may play important roles in regulating GIST
metastasis. The NIH classification published in 2002 was widely
accepted as standard for predicting the prognosis of GIST patients
[27,28]. According to the NIH classification, the risk assessments are
based on tumor size and the number of mitotic figures. We have
analyzed the correlation between CTHRC1 expression and GIST
clinicopathological parameters and found that the CTHRC1
Figure 8. (A) The pro-invasion effect of rCTHRC1 protein was blocked by Wnt5a neutralizing antibody but not blocked by Wnt3a
neutralizing antibody shown from cell invasion assay in vitro. (B) Quantification analysis of migrated cells were performed for six randomly
selected fields (original magnification: 200×). (C) The pro-invasion effect of rCTHRC1 protein was partially blocked by Rac1 inhibitor
(NSC23766) as well as ROCK inhibitor (Y-27632) shown from cell invasion assay. (D) Quantification analysis of migrated cells were
performed for six randomly selected fields (original magnification:200×). (*, P b 0.05; **, P b 0.01).
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and the number of mitotic figures. These analyses suggest that
CTHRC1-positive GISTs exhibit a greater likelihood of malignant
behavior and more aggressive features. Moreover, there was a
significant difference between male and female GIST patients in
frequency of high CTHRC1 levels (Table 1). It has been reported
that CTHRC1 is associated with attenuated inflammatory arthritis
severity in males, but not in females [29,30]. The naive mice assay
showed that the expression and inducibility of CTHRC1 were highly
dependent on sex [29,30]. Among naive wild-type BALB/c mice,
CTHRC1 expression was remarkably higher in males than in females.
Moreover, CTHRC1 was one of the major sex-affected differentially
expressed genes [29,30]. Therefore, sex disparities may cause the
difference between male and female GIST patients in high CTHRC1
expression rates.
The Kaplan-Meier curves analysis revealed that CTHRC1
expression was closely correlated with OS and DFS of GIST patients.
GIST patients with CTHRC1-positive tumors had shorter OS and
DFS than CTHRC1-negative patients. Therefore, we identified thatCTHRC1 is an available predictor of poor prognosis including OS
and DFS in GIST patients. In addition, the great clinical value of
CTHRC1 in predicting the recurrence risk of postoperative GIST
patients may contribute to improving the clinical therapeutic effects.
Tumor microenvironments including components of extracellular
matrix protein play crucial roles in promoting tumor invasion and
metastasis [31]. CTHRC1, a secreted ECM protein, has been
reported to be up-regulated in many solid tumors. In hepatocellular
carcinoma, CTHRC1 is up-regulated and promotes tumor invasion
and predicts poor prognosis [13]. CTHRC1 plays a promoting role in
pancreatic cancer progression and metastasis by enhancing the
migration ability of cancer cells [18]. These accumulating data
indicate that CTHRC1 is an important regulator of tumor invasion
and metastasis in the tumor microenvironment. In the present study,
we have found that CTHRC1 expression in GIST tissue is gradually
elevated in accordance with risk grading. Based on an in vitro
functional assay, CTHRC1 was considered to be an invasion-
promoting protein and ultimately contributed to gastrointestinal
stromal tumor metastasis and recurrence.
Figure 9. CTHRC1 induced cell signaling alteration and its related cell movement.
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invasion and metastasis have been well established, the underlying
mechanisms of how CTHRC1 promotes cancer cell invasion
remains unclear. It has been reported that CTHRC1 acts as a Wnt
cofactor that selectively activates the PCP pathway in the inner ear
developmental process [17]. In the present study, we showed that
CTHRC1 promotes GIST cell invasion by activating Wnt/PCP
signaling, which is supported by the following evidence. First, the
luciferase reporter assay and western blotting showed that
recombinant CTHRC1 protein activated the PCP pathway of
Wnt signaling of primary GIST cells in a dose-dependent manner.
Second, the pro-invasion activity of the rCTHRC1 protein was
blocked by the neutralizing antibody of Wnt5a (a ligand for Wnt/PCP
pathway [32,33]) and the inhibitors of Rac1 and ROCK (the
downstream molecules of Wnt/PCP signaling [34,35]).
CTHRC1 promoted tumor cells migration by activating Rac1 and
resulted in metastasis of pancreatic cancer [18]. The overexpression of
CTHRC1 promotes tumor invasion by activating RhoA in
hepatocellular carcinoma [13]. Accordingly, we demonstrated the
promoting effect of CTHRC1 on both RhoA and Rac1 in GIST cells.Moreover, we further verified that the pro-invasion activity of
CTHRC1 in GIST cells was dependent on the Wnt5a/PCP-Rho axis
by blocking the Wnt5a/PCP-Rho pathway with neutralizing
antibodies and specific inhibitors. The noncanonical Wnt/PCP
pathway transmits signaling from the cell-surface Frizzled receptor-
coupled Wnt5a protein, via the Dvl-RhoA/Rac1-JNK-ATF2/c-Jun
cascade [36-38], to the nucleus. Noncanonical Wnt/PCP signaling
plays important roles in promoting cell migration [39] and formation
of cell protrusions [40,41]. The small Rho GTPases Rac1, RhoA and
Cdc42, are key executors of Wnt/PCP related cell migration [42,43].
RhoA controls the assembly of actin to generate contractile forces
[44,45], while Rac1 and Cdc42 promote actin polymerization
contributing to the formation of protrusive forces [46,47]. Therefore,
the efficient cell movement requires synergistic actions of the three
Rho GTPases [48-50]. In this study, we have shown that CTHRC1, a
secreted protein, transduces outside-in signals through the Wnt/PCP
pathway and coordinates the action of the three Rho GTPases to
promote GIST cell migration and invasion.
Taken together, we have demonstrated that CTHRC1 expres-
sion level is closely correlated with risk grade of NIH classification
Neoplasia Vol. 16, No. 3, March 2014 CTHRC1 Promotes Invasion of Gastrointestinal Stromal Tumors Ma et al. 277and prognosis of GIST, indicating that CTHRC1 served as a new
predictor of recurrence risk and prognosis in post-operative GIST
patients. Furthermore, we have shown that CTHRC1 promotes
GIST cell migration and invasion by activating the Wnt/PCP-Rho
signaling, suggesting that the CTHRC1- Wnt/PCP-Rho axis may
be a new therapeutic target for interventions against GIST invasion
and metastasis.
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metastatic GIST and primary GIST based on data from GEO
Database (GSE21315). (B) Schematic diagram of V152 vector
which was used to reconstruct CTHRC1-StrepII recombinant
plasmid.
Figure W2. Verification of affinity purified CTHRC1 protein by
Coomassie Brilliant Blue staining and Western blotting.
Figure W3. Negative controls for primary and secondary antibodies in GIST TMA immunohistochemistry staining assay (original
magnification:100×).
Table W1. ANOVA analysis (post-hoc testing) for statistics of figures.
Multiple Comparisons
(I) 1 = low risk,
2 = intermediate risk,
3 = high risk
(J) 1 = low risk,
2 = intermediate risk,
3 = high risk
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 1A
1 2 −1.53243 * .57014 .031 −2.9405 -.1244
3 −1.47190 * .58777 .046 −2.9235 -.0203
2 1 1.53243 * .57014 .031 .1244 2.9405
3 .06053 .62280 .995 −1.4776 1.5986
3 1 1.47190 * .58777 .046 .0203 2.9235
2 -.06053 .62280 .995 −1.5986 1.4776
VAR00001
Tukey HSD
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day0
0 1 -.0040000 .0094810 .973 -.034361 .026361
20 -.0160000 .0094810 .389 -.046361 .014361
50 -.0013333 .0094810 .999 -.031695 .029028
1 0 .0040000 .0094810 .973 -.026361 .034361
20 -.0120000 .0094810 .607 -.042361 .018361
50 .0026667 .0094810 .992 -.027695 .033028
20 0 .0160000 .0094810 .389 -.014361 .046361
1 .0120000 .0094810 .607 -.018361 .042361
50 .0146667 .0094810 .456 -.015695 .045028
50 0 .0013333 .0094810 .999 -.029028 .031695
1 -.0026667 .0094810 .992 -.033028 .027695
20 -.0146667 .0094810 .456 -.045028 .015695
VAR00001
Tukey HSD
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Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day1
0 1 .0023333 .0055578 .973 -.015465 .020131
20 -.0216667 * .0055578 .019 -.039465 -.003869
50 -.0230000 * .0055578 .014 -.040798 -.005202
1 0 -.0023333 .0055578 .973 -.020131 .015465
20 -.0240000 * .0055578 .011 -.041798 -.006202
50 -.0253333 * .0055578 .008 -.043131 -.007535
20 0 .0216667 * .0055578 .019 .003869 .039465
1 .0240000 * .0055578 .011 .006202 .041798
50 -.0013333 .0055578 .995 -.019131 .016465
50 0 .0230000 * .0055578 .014 .005202 .040798
1 .0253333 * .0055578 .008 .007535 .043131
20 .0013333 .0055578 .995 -.016465 .019131
VAR00001
Tukey HSD
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day2
0 1 -.0596667 * .0133083 .009 -.102285 -.017049
20 -.0253333 .0133083 .299 -.067951 .017285
50 -.0746667 * .0133083 .002 -.117285 -.032049
1 0 .0596667 * .0133083 .009 .017049 .102285
20 .0343333 .0133083 .120 -.008285 .076951
50 -.0150000 .0133083 .684 -.057618 .027618
20 0 .0253333 .0133083 .299 -.017285 .067951
1 -.0343333 .0133083 .120 -.076951 .008285
50 -.0493333 * .0133083 .025 -.091951 -.006715
50 0 .0746667 * .0133083 .002 .032049 .117285
1 .0150000 .0133083 .684 -.027618 .057618
20 .0493333 * .0133083 .025 .006715 .091951
VAR00001
Tukey HSD
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day3
0 1 -.0046667 .0051962 .806 -.021307 .011973
20 -.0223333 * .0051962 .011 -.038973 -.005693
50 -.0283333 * .0051962 .003 -.044973 -.011693
1 0 .0046667 .0051962 .806 -.011973 .021307
20 -.0176667 * .0051962 .038 -.034307 -.001027
50 -.0236667 * .0051962 .008 -.040307 -.007027
20 0 .0223333 * .0051962 .011 .005693 .038973
1 .0176667 * .0051962 .038 .001027 .034307
50 -.0060000 .0051962 .669 -.022640 .010640
50 0 .0283333 * .0051962 .003 .011693 .044973
1 .0236667 * .0051962 .008 .007027 .040307
20 .0060000 .0051962 .669 -.010640 .022640
VAR00001
Tukey HSD
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Table W1. (continued)
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day4
0 1 -.0030000 .0072111 .974 -.026092 .020092
20 .0173333 .0072111 .154 -.005759 .040426
50 -.0753333 * .0072111 .000 -.098426 -.052241
1 0 .0030000 .0072111 .974 -.020092 .026092
20 .0203333 .0072111 .086 -.002759 .043426
50 -.0723333 * .0072111 .000 -.095426 -.049241
20 0 -.0173333 .0072111 .154 -.040426 .005759
1 -.0203333 .0072111 .086 -.043426 .002759
50 -.0926667 * .0072111 .000 -.115759 -.069574
50 0 .0753333 * .0072111 .000 .052241 .098426
1 .0723333 * .0072111 .000 .049241 .095426
20 .0926667 * .0072111 .000 .069574 .115759
VAR00001
Tukey HSD
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day5
0 1 .0146667 .0078916 .316 -.010605 .039938
20 -.0660000 * .0078916 .000 -.091272 -.040728
50 -.0893333 * .0078916 .000 -.114605 -.064062
1 0 -.0146667 .0078916 .316 -.039938 .010605
20 -.0806667 * .0078916 .000 -.105938 -.055395
50 -.1040000 * .0078916 .000 -.129272 -.078728
20 0 .0660000 * .0078916 .000 .040728 .091272
1 .0806667 * .0078916 .000 .055395 .105938
50 -.0233333 .0078916 .071 -.048605 .001938
50 0 .0893333 * .0078916 .000 .064062 .114605
1 .1040000 * .0078916 .000 .078728 .129272
20 .0233333 .0078916 .071 -.001938 .048605
VAR00001
Tukey HSD
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3B
Day6
0 1 -.0046667 .0106797 .970 -.038867 .029533
20 -.0750000 * .0106797 .001 -.109200 -.040800
50 -.1590000 * .0106797 .000 -.193200 -.124800
1 0 .0046667 .0106797 .970 -.029533 .038867
20 -.0703333 * .0106797 .001 -.104533 -.036133
50 -.1543333 * .0106797 .000 -.188533 -.120133
20 0 .0750000 * .0106797 .001 .040800 .109200
1 .0703333 * .0106797 .001 .036133 .104533
50 -.0840000 * .0106797 .000 -.118200 -.049800
50 0 .1590000 * .0106797 .000 .124800 .193200
1 .1543333 * .0106797 .000 .120133 .188533
20 .0840000 * .0106797 .000 .049800 .118200
VAR00001
Tukey HSD
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Table W1. (continued)
Table W1. (continued)
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3C
0 1 −6.50000 * 1.69558 .005 −11.2458 −1.7542
20 −55.50000 * 1.69558 .000 −60.2458 −50.7542
50 −69.16667 * 1.69558 .000 −73.9125 −64.4208
1 0 6.50000 * 1.69558 .005 1.7542 11.2458
20 −49.00000 * 1.69558 .000 −53.7458 −44.2542
50 −62.66667 * 1.69558 .000 −67.4125 −57.9208
20 0 55.50000 * 1.69558 .000 50.7542 60.2458
1 49.00000 * 1.69558 .000 44.2542 53.7458
50 −13.66667 * 1.69558 .000 −18.4125 −8.9208
50 0 69.16667 * 1.69558 .000 64.4208 73.9125
1 62.66667 * 1.69558 .000 57.9208 67.4125
20 13.66667 * 1.69558 .000 8.9208 18.4125
VAR00001
Tukey HSD
Multiple Comparisons
(I) concentration (J) concentration Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 3D
0 1 −23.66667 * 3.28549 .000 −32.8625 −14.4708
20 −55.50000 * 3.28549 .000 −64.6959 −46.3041
50 −72.16667 * 3.28549 .000 −81.3625 −62.9708
1 0 23.66667 * 3.28549 .000 14.4708 32.8625
20 −31.83333 * 3.28549 .000 −41.0292 −22.6375
50 −48.50000 * 3.28549 .000 −57.6959 −39.3041
20 0 55.50000 * 3.28549 .000 46.3041 64.6959
1 31.83333 * 3.28549 .000 22.6375 41.0292
50 −16.66667 * 3.28549 .000 −25.8625 −7.4708
50 0 72.16667 * 3.28549 .000 62.9708 81.3625
1 48.50000 * 3.28549 .000 39.3041 57.6959
20 16.66667 * 3.28549 .000 7.4708 25.8625
VAR00001
Tukey HSD
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4A (Mutant TCF)
0 1 -.01200 .02143 .941 -.0806 .0566
20 -.02933 .02143 .550 -.0980 .0393
50 -.04333 .02143 .257 -.1120 .0253
1 0 .01200 .02143 .941 -.0566 .0806
20 -.01733 .02143 .849 -.0860 .0513
50 -.03133 .02143 .500 -.1000 .0373
20 0 .02933 .02143 .550 -.0393 .0980
1 .01733 .02143 .849 -.0513 .0860
50 -.01400 .02143 .911 -.0826 .0546
50 0 .04333 .02143 .257 -.0253 .1120
1 .03133 .02143 .500 -.0373 .1000
20 .01400 .02143 .911 -.0546 .0826
VAR00001
Tukey HSD
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Table W1. (continued)
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4A (TCF)
0 1 .19167 * .02076 .000 .1252 .2582
20 .30900 * .02076 .000 .2425 .3755
50 .46600 * .02076 .000 .3995 .5325
1 0 -.19167 * .02076 .000 -.2582 -.1252
20 .11733 * .02076 .002 .0508 .1838
50 .27433 * .02076 .000 .2078 .3408
20 0 -.30900 * .02076 .000 -.3755 -.2425
1 -.11733 * .02076 .002 -.1838 -.0508
50 .15700 * .02076 .000 .0905 .2235
50 0 -.46600 * .02076 .000 -.5325 -.3995
1 -.27433 * .02076 .000 -.3408 -.2078
20 -.15700 * .02076 .000 -.2235 -.0905
VAR00001
Tukey HSD
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4B
0 1 −1.92467 * .41532 .007 −3.2547 -.5947
20 −2.50733 * .41532 .001 −3.8373 −1.1773
50 −6.96000 * .41532 .000 −8.2900 −5.6300
1 0 1.92467 * .41532 .007 .5947 3.2547
20 -.58267 .41532 .531 −1.9127 .7473
50 −5.03533 * .41532 .000 −6.3653 −3.7053
20 0 2.50733 * .41532 .001 1.1773 3.8373
1 .58267 .41532 .531 -.7473 1.9127
50 −4.45267 * .41532 .000 −5.7827 −3.1227
50 0 6.96000 * .41532 .000 5.6300 8.2900
1 5.03533 * .41532 .000 3.7053 6.3653
20 4.45267 * .41532 .000 3.1227 5.7827
VAR00001
Tukey HSD
Multiple Comparisons
(I) 1 = 0nm,
2 = 20nm,
3 = 0nm+Wnt5a mAb,
4 = 20nm+Wnt5a mAb
(J) 1 = 0nm,
2 = 20nm,
3 = 0nm+Wnt5a mAb,
4 = 20nm+Wnt5a mAb
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4C
1 2 .33467 * .03334 .000 .2279 .4414
3 .04400 .03334 .577 -.0628 .1508
4 .16100 * .03334 .006 .0542 .2678
2 1 -.33467 * .03334 .000 -.4414 -.2279
3 -.29067 * .03334 .000 -.3974 -.1839
4 -.17367 * .03334 .004 -.2804 -.0669
3 1 -.04400 .03334 .577 -.1508 .0628
2 .29067 * .03334 .000 .1839 .3974
4 .11700 * .03334 .033 .0102 .2238
4 1 -.16100 * .03334 .006 -.2678 -.0542
2 .17367 * .03334 .004 .0669 .2804
3 -.11700 * .03334 .033 -.2238 -.0102
VAR00001
Tukey HSD
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Table W1. (continued)
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4D
1 2 −2.75433 * .27391 .000 −3.6315 −1.8772
3 1.07233 * .27391 .019 .1952 1.9495
4 -.32100 .27391 .659 −1.1981 .5561
2 1 2.75433 * .27391 .000 1.8772 3.6315
3 3.82667 * .27391 .000 2.9495 4.7038
4 2.43333 * .27391 .000 1.5562 3.3105
3 1 −1.07233 * .27391 .019 −1.9495 -.1952
2 −3.82667 * .27391 .000 −4.7038 −2.9495
4 −1.39333 * .27391 .004 −2.2705 -.5162
4 1 .32100 .27391 .659 -.5561 1.1981
2 −2.43333 * .27391 .000 −3.3105 −1.5562
3 1.39333 * .27391 .004 .5162 2.2705
VAR00001
Tukey HSD
Multiple Comparisons
(I) 1 = NC,
2 = +Wnt3a,
3 = +Wnt3a mAb,
4 = Wnt3a+Wnt3a mAb
(J) 1 = NC,
2 = +Wnt3a,
3 = +Wnt3a mAb,
4 = Wnt3a+Wnt3a mAb
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4E
1 2 -.47433 * .04523 .000 -.6192 -.3295
3 .17733 * .04523 .019 .0325 .3222
4 .16567 * .04523 .026 .0208 .3105
2 1 .47433 * .04523 .000 .3295 .6192
3 .65167 * .04523 .000 .5068 .7965
4 .64000 * .04523 .000 .4951 .7849
3 1 -.17733 * .04523 .019 -.3222 -.0325
2 -.65167 * .04523 .000 -.7965 -.5068
4 -.01167 .04523 .994 -.1565 .1332
4 1 -.16567 * .04523 .026 -.3105 -.0208
2 -.64000 * .04523 .000 -.7849 -.4951
3 .01167 .04523 .994 -.1332 .1565
VAR00001
Tukey HSD
Multiple Comparisons
(I) 1 = NC,
2 = +Wnt5a,
3 = +Wnt5a mAb,
4 = Wnt5a+Wnt5a mAb
(J) 1 = NC,
2 = +Wnt5a,
3 = +Wnt5a mAb,
4 = Wnt5a+Wnt5a mAb
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 4F
1 2 −3.02767 * .20239 .000 −3.6758 −2.3795
3 1.02867 * .20239 .004 .3805 1.6768
4 -.17100 .20239 .832 -.8191 .4771
2 1 3.02767 * .20239 .000 2.3795 3.6758
3 4.05633 * .20239 .000 3.4082 4.7045
4 2.85667 * .20239 .000 2.2085 3.5048
3 1 −1.02867 * .20239 .004 −1.6768 -.3805
2 −4.05633 * .20239 .000 −4.7045 −3.4082
4 −1.19967 * .20239 .002 −1.8478 -.5515
4 1 .17100 .20239 .832 -.4771 .8191
2 −2.85667 * .20239 .000 −3.5048 −2.2085
3 1.19967 * .20239 .002 .5515 1.8478
VAR00001
Tukey HSD
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Table W1. (continued)
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 5B
0 5 -.58300 * .05290 .000 -.7571 -.4089
10 -.12600 .05290 .197 -.3001 .0481
30 -.40433 * .05290 .000 -.5784 -.2302
60 -.13600 .05290 .150 -.3101 .0381
5 0 .58300 * .05290 .000 .4089 .7571
10 .45700 * .05290 .000 .2829 .6311
30 .17867 * .05290 .044 .0046 .3528
60 .44700 * .05290 .000 .2729 .6211
10 0 .12600 .05290 .197 -.0481 .3001
5 -.45700 * .05290 .000 -.6311 -.2829
30 -.27833 * .05290 .003 -.4524 -.1042
60 -.01000 .05290 1.000 -.1841 .1641
30 0 .40433 * .05290 .000 .2302 .5784
5 -.17867 * .05290 .044 -.3528 -.0046
10 .27833 * .05290 .003 .1042 .4524
60 .26833 * .05290 .003 .0942 .4424
60 0 .13600 .05290 .150 -.0381 .3101
5 -.44700 * .05290 .000 -.6211 -.2729
10 .01000 .05290 1.000 -.1641 .1841
30 -.26833 * .05290 .003 -.4424 -.0942
VAR00001
Tukey HSD
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 5C
0 5 -.20667 * .01588 .000 -.2589 -.1544
10 -.39767 * .01588 .000 -.4499 -.3454
30 -.52167 * .01588 .000 -.5739 -.4694
60 -.53733 * .01588 .000 -.5896 -.4851
5 0 .20667 * .01588 .000 .1544 .2589
10 -.19100 * .01588 .000 -.2433 -.1387
30 -.31500 * .01588 .000 -.3673 -.2627
60 -.33067 * .01588 .000 -.3829 -.2784
10 0 .39767 * .01588 .000 .3454 .4499
5 .19100 * .01588 .000 .1387 .2433
30 -.12400 * .01588 .000 -.1763 -.0717
60 -.13967 * .01588 .000 -.1919 -.0874
30 0 .52167 * .01588 .000 .4694 .5739
5 .31500 * .01588 .000 .2627 .3673
10 .12400 * .01588 .000 .0717 .1763
60 -.01567 .01588 .855 -.0679 .0366
60 0 .53733 * .01588 .000 .4851 .5896
5 .33067 * .01588 .000 .2784 .3829
10 .13967 * .01588 .000 .0874 .1919
30 .01567 .01588 .855 -.0366 .0679
VAR00001
Tukey HSD
Multiple Comparisons
(I) time (J) time Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 5D
0 5 .03000 .03961 .937 -.1004 .1604
10 -.01000 .03961 .999 -.1404 .1204
30 .00667 .03961 1.000 -.1237 .1370
60 -.02333 .03961 .974 -.1537 .1070
5 0 -.03000 .03961 .937 -.1604 .1004
10 -.04000 .03961 .845 -.1704 .0904
30 -.02333 .03961 .974 -.1537 .1070
60 -.05333 .03961 .671 -.1837 .0770
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Table W1. (continued)
10 0 .01000 .03961 .999 -.1204 .1404
5 .04000 .03961 .845 -.0904 .1704
30 .01667 .03961 .992 -.1137 .1470
60 -.01333 .03961 .997 -.1437 .1170
30 0 -.00667 .03961 1.000 -.1370 .1237
5 .02333 .03961 .974 -.1070 .1537
10 -.01667 .03961 .992 -.1470 .1137
60 -.03000 .03961 .937 -.1604 .1004
60 0 .02333 .03961 .974 -.1070 .1537
5 .05333 .03961 .671 -.0770 .1837
10 .01333 .03961 .997 -.1170 .1437
30 .03000 .03961 .937 -.1004 .1604
VAR00001
Tukey HSD
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 5E
0 1 -.11033 * .02696 .015 -.1967 -.0240
20 -.32633 * .02696 .000 -.4127 -.2400
50 -.47333 * .02696 .000 -.5597 -.3870
1 0 .11033 * .02696 .015 .0240 .1967
20 -.21600 * .02696 .000 -.3023 -.1297
50 -.36300 * .02696 .000 -.4493 -.2767
20 0 .32633 * .02696 .000 .2400 .4127
1 .21600 * .02696 .000 .1297 .3023
50 -.14700 * .02696 .003 -.2333 -.0607
50 0 .47333 * .02696 .000 .3870 .5597
1 .36300 * .02696 .000 .2767 .4493
20 .14700 * .02696 .003 .0607 .2333
VAR00001
Tukey HSD
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 5F
0 1 -.15167 * .01790 .000 -.2090 -.0943
20 -.39267 * .01790 .000 -.4500 -.3353
50 -.51900 * .01790 .000 -.5763 -.4617
1 0 .15167 * .01790 .000 .0943 .2090
20 -.24100 * .01790 .000 -.2983 -.1837
50 -.36733 * .01790 .000 -.4247 -.3100
20 0 .39267 * .01790 .000 .3353 .4500
1 .24100 * .01790 .000 .1837 .2983
50 -.12633 * .01790 .000 -.1837 -.0690
50 0 .51900 * .01790 .000 .4617 .5763
1 .36733 * .01790 .000 .3100 .4247
20 .12633 * .01790 .000 .0690 .1837
VAR00001
Tukey HSD
Multiple Comparisons
(I) VAR00002 (J) VAR00002 Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 6C
0 5 -.08967 * .02012 .008 -.1559 -.0234
10 -.37167 * .02012 .000 -.4379 -.3054
30 -.56933 * .02012 .000 -.6356 -.5031
60 -.74133 * .02012 .000 -.8076 -.6751
5 0 .08967 * .02012 .008 .0234 .1559
10 -.28200 * .02012 .000 -.3482 -.2158
30 -.47967 * .02012 .000 -.5459 -.4134
60 -.65167 * .02012 .000 -.7179 -.5854
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Table W1. (continued)
10 0 .37167 * .02012 .000 .3054 .4379
5 .28200 * .02012 .000 .2158 .3482
30 -.19767 * .02012 .000 -.2639 -.1314
60 -.36967 * .02012 .000 -.4359 -.3034
30 0 .56933 * .02012 .000 .5031 .6356
5 .47967 * .02012 .000 .4134 .5459
10 .19767 * .02012 .000 .1314 .2639
60 -.17200 * .02012 .000 -.2382 -.1058
60 0 .74133 * .02012 .000 .6751 .8076
5 .65167 * .02012 .000 .5854 .7179
10 .36967 * .02012 .000 .3034 .4359
30 .17200 * .02012 .000 .1058 .2382
VAR00001
Tukey HSD
Multiple Comparisons
(I) time (J) time Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 6D
0 5 -.23467 * .02028 .000 -.3014 -.1679
10 -.82533 * .02028 .000 -.8921 -.7586
30 -.68733 * .02028 .000 -.7541 -.6206
60 -.46233 * .02028 .000 -.5291 -.3956
5 0 .23467 * .02028 .000 .1679 .3014
10 -.59067 * .02028 .000 -.6574 -.5239
30 -.45267 * .02028 .000 -.5194 -.3859
60 -.22767 * .02028 .000 -.2944 -.1609
10 0 .82533 * .02028 .000 .7586 .8921
5 .59067 * .02028 .000 .5239 .6574
30 .13800 * .02028 .000 .0712 .2048
60 .36300 * .02028 .000 .2962 .4298
30 0 .68733 * .02028 .000 .6206 .7541
5 .45267 * .02028 .000 .3859 .5194
10 -.13800 * .02028 .000 -.2048 -.0712
60 .22500 * .02028 .000 .1582 .2918
60 0 .46233 * .02028 .000 .3956 .5291
5 .22767 * .02028 .000 .1609 .2944
10 -.36300 * .02028 .000 -.4298 -.2962
30 -.22500 * .02028 .000 -.2918 -.1582
VAR00001
Tukey HSD
Multiple Comparisons
(I) time (J) time Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 6E
0 5 .02467 .02220 .797 -.0484 .0977
10 -.33967 * .02220 .000 -.4127 -.2666
30 -.26100 * .02220 .000 -.3341 -.1879
60 -.37767 * .02220 .000 -.4507 -.3046
5 0 -.02467 .02220 .797 -.0977 .0484
10 -.36433 * .02220 .000 -.4374 -.2913
30 -.28567 * .02220 .000 -.3587 -.2126
60 -.40233 * .02220 .000 -.4754 -.3293
10 0 .33967 * .02220 .000 .2666 .4127
5 .36433 * .02220 .000 .2913 .4374
30 .07867 * .02220 .034 .0056 .1517
60 -.03800 .02220 .469 -.1111 .0351
30 0 .26100 * .02220 .000 .1879 .3341
5 .28567 * .02220 .000 .2126 .3587
10 -.07867 * .02220 .034 -.1517 -.0056
60 -.11667 * .02220 .003 -.1897 -.0436
60 0 .37767 * .02220 .000 .3046 .4507
5 .40233 * .02220 .000 .3293 .4754
10 .03800 .02220 .469 -.0351 .1111
30 .11667 * .02220 .003 .0436 .1897
data
Tukey HSD
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Table W1. (continued)
Multiple Comparisons
(I) time (J) time Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 6F
0 5 -.43533 * .01941 .000 -.4992 -.3715
10 -.83733 * .01941 .000 -.9012 -.7735
30 -.77067 * .01941 .000 -.8345 -.7068
60 -.78267 * .01941 .000 -.8465 -.7188
5 0 .43533 * .01941 .000 .3715 .4992
10 -.40200 * .01941 .000 -.4659 -.3381
30 -.33533 * .01941 .000 -.3992 -.2715
60 -.34733 * .01941 .000 -.4112 -.2835
10 0 .83733 * .01941 .000 .7735 .9012
5 .40200 * .01941 .000 .3381 .4659
30 .06667 * .01941 .040 .0028 .1305
60 .05467 .01941 .104 -.0092 .1185
30 0 .77067 * .01941 .000 .7068 .8345
5 .33533 * .01941 .000 .2715 .3992
10 -.06667 * .01941 .040 -.1305 -.0028
60 -.01200 .01941 .969 -.0759 .0519
60 0 .78267 * .01941 .000 .7188 .8465
5 .34733 * .01941 .000 .2835 .4112
10 -.05467 .01941 .104 -.1185 .0092
30 .01200 .01941 .969 -.0519 .0759
data
Tukey HSD
Multiple Comparisons
(I) 1 = 0nm,
2 = 20nm,
3 = 0nm+Wnt3a mAb,
4 = 20nm+Wnt3a mAb,
5 = 0nm+Wnt5a mAb,
6 = 20nm+Wnt5a mAb
(J) 1 = 0nm,
2 = 20nm,
3 = 0nm+Wnt3a mAb,
4 = 20nm+Wnt3a mAb,
5 = 0nm+Wnt5a mAb,
6 = 20nm+Wnt5a mAb
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 7B
1 2 −53.00000 * 4.10916 .000 −65.4984 −40.5016
3 -.33333 4.10916 1.000 −12.8317 12.1651
4 −49.50000 * 4.10916 .000 −61.9984 −37.0016
5 −4.50000 4.10916 .879 −16.9984 7.9984
6 −13.33333 * 4.10916 .031 −25.8317 -.8349
2 1 53.00000 * 4.10916 .000 40.5016 65.4984
3 52.66667 * 4.10916 .000 40.1683 65.1651
4 3.50000 4.10916 .955 −8.9984 15.9984
5 48.50000 * 4.10916 .000 36.0016 60.9984
6 39.66667 * 4.10916 .000 27.1683 52.1651
3 1 .33333 4.10916 1.000 −12.1651 12.8317
2 −52.66667 * 4.10916 .000 −65.1651 −40.1683
4 −49.16667 * 4.10916 .000 −61.6651 −36.6683
5 −4.16667 4.10916 .910 −16.6651 8.3317
6 −13.00000 * 4.10916 .038 −25.4984 -.5016
4 1 49.50000 * 4.10916 .000 37.0016 61.9984
2 −3.50000 4.10916 .955 −15.9984 8.9984
3 49.16667 * 4.10916 .000 36.6683 61.6651
5 45.00000 * 4.10916 .000 32.5016 57.4984
6 36.16667 * 4.10916 .000 23.6683 48.6651
5 1 4.50000 4.10916 .879 −7.9984 16.9984
2 −48.50000 * 4.10916 .000 −60.9984 −36.0016
3 4.16667 4.10916 .910 −8.3317 16.6651
4 −45.00000 * 4.10916 .000 −57.4984 −32.5016
6 −8.83333 4.10916 .290 −21.3317 3.6651
6 1 13.33333 * 4.10916 .031 .8349 25.8317
2 −39.66667 * 4.10916 .000 −52.1651 −27.1683
3 13.00000 * 4.10916 .038 .5016 25.4984
4 −36.16667 * 4.10916 .000 −48.6651 −23.6683
5 8.83333 4.10916 .290 −3.6651 21.3317
VAR00001
Tukey HSD
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Table W1. (continued)
Multiple Comparisons
(I) 1 = 0nm,
2 = 20nm,
3 = 0nm+NSC23766,
4 = 20nm+NSC23766,
5 = 0nm+Y-27632,
6 = 20nm+Y-27632
(J) 1 = 0nm,
2 = 20nm,
3 = 0nm+NSC23766,
4 = 20nm+NSC23766,
5 = 0nm+Y-27632,
6 = 20nm+Y-27632
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 7D
1 2 −51.00000 * 2.31541 .000 −58.0425 −43.9575
3 −4.16667 2.31541 .481 −11.2092 2.8759
4 −15.50000 * 2.31541 .000 −22.5425 −8.4575
5 −7.16667 * 2.31541 .044 −14.2092 -.1241
6 −11.00000 * 2.31541 .001 −18.0425 −3.9575
2 1 51.00000 * 2.31541 .000 43.9575 58.0425
3 46.83333 * 2.31541 .000 39.7908 53.8759
4 35.50000 * 2.31541 .000 28.4575 42.5425
5 43.83333 * 2.31541 .000 36.7908 50.8759
6 40.00000 * 2.31541 .000 32.9575 47.0425
3 1 4.16667 2.31541 .481 −2.8759 11.2092
2 −46.83333 * 2.31541 .000 −53.8759 −39.7908
4 −11.33333 * 2.31541 .000 −18.3759 −4.2908
5 −3.00000 2.31541 .785 −10.0425 4.0425
6 −6.83333 2.31541 .061 −13.8759 .2092
4 1 15.50000 * 2.31541 .000 8.4575 22.5425
2 −35.50000 * 2.31541 .000 −42.5425 −28.4575
3 11.33333 * 2.31541 .000 4.2908 18.3759
5 8.33333 * 2.31541 .013 1.2908 15.3759
6 4.50000 2.31541 .397 −2.5425 11.5425
5 1 7.16667 * 2.31541 .044 .1241 14.2092
2 −43.83333 * 2.31541 .000 −50.8759 −36.7908
3 3.00000 2.31541 .785 −4.0425 10.0425
4 −8.33333 * 2.31541 .013 −15.3759 −1.2908
6 −3.83333 2.31541 .570 −10.8759 3.2092
6 1 11.00000 * 2.31541 .001 3.9575 18.0425
2 −40.00000 * 2.31541 .000 −47.0425 −32.9575
3 6.83333 2.31541 .061 -.2092 13.8759
4 −4.50000 2.31541 .397 −11.5425 2.5425
5 3.83333 2.31541 .570 −3.2092 10.8759
VAR00001
Tukey HSD
Multiple Comparisons
(I) 1 = 0nm,
2 = 20nm,
3 = 0nm+Wnt3a mAb,
4 = 20nm+Wnt3a mAb,
5 = 0nm+Wnt5a mAb,
6 = 20nm+Wnt5a mAb
(J) 1 = 0nm,
2 = 20nm,
3 = 0nm+Wnt3a mAb,
4 = 20nm+Wnt3a mAb,
5 = 0nm+Wnt5a mAb,
6 = 20nm+Wnt5a mAb
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 8B
1 2 −71.83333 * 3.48250 .000 −82.4257 −61.2410
3 1.00000 3.48250 1.000 −9.5923 11.5923
4 −65.33333 * 3.48250 .000 −75.9257 −54.7410
5 −1.00000 3.48250 1.000 −11.5923 9.5923
6 −9.33333 3.48250 .109 −19.9257 1.2590
2 1 71.83333 * 3.48250 .000 61.2410 82.4257
3 72.83333 * 3.48250 .000 62.2410 83.4257
4 6.50000 3.48250 .441 −4.0923 17.0923
5 70.83333 * 3.48250 .000 60.2410 81.4257
6 62.50000 * 3.48250 .000 51.9077 73.0923
3 1 −1.00000 3.48250 1.000 −11.5923 9.5923
2 −72.83333 * 3.48250 .000 −83.4257 −62.2410
4 −66.33333 * 3.48250 .000 −76.9257 −55.7410
5 −2.00000 3.48250 .992 −12.5923 8.5923
6 −10.33333 3.48250 .059 −20.9257 .2590
4 1 65.33333 * 3.48250 .000 54.7410 75.9257
2 −6.50000 3.48250 .441 −17.0923 4.0923
3 66.33333 * 3.48250 .000 55.7410 76.9257
5 64.33333 * 3.48250 .000 53.7410 74.9257
6 56.00000 * 3.48250 .000 45.4077 66.5923
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Table W1. (continued)
5 1 1.00000 3.48250 1.000 −9.5923 11.5923
2 −70.83333 * 3.48250 .000 −81.4257 −60.2410
3 2.00000 3.48250 .992 −8.5923 12.5923
4 −64.33333 * 3.48250 .000 −74.9257 −53.7410
6 −8.33333 3.48250 .191 −18.9257 2.2590
6 1 9.33333 3.48250 .109 −1.2590 19.9257
2 −62.50000 * 3.48250 .000 −73.0923 −51.9077
3 10.33333 3.48250 .059 -.2590 20.9257
4 −56.00000 * 3.48250 .000 −66.5923 −45.4077
5 8.33333 3.48250 .191 −2.2590 18.9257
VAR00001
Tukey HSD
Multiple Comparisons
(I) 1 = 0nm,
2 = 20nm,
3 = 0nm+NSC23766,
4 = 20nm+NSC23766,
5 = 0nm+Y-27632,
6 = 20nm+Y-27632
(J) 1 = 0nm,
2 = 20nm,
3 = 0nm+NSC23766,
4 = 20nm+NSC23766,
5 = 0nm+Y-27632,
6 = 20nm+Y-27632
Mean Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound
Figure 8D
1 2 −78.00000 * 3.68053 .000 −89.1947 −66.8053
3 −4.16667 3.68053 .864 −15.3613 7.0280
4 −5.50000 3.68053 .670 −16.6947 5.6947
5 3.16667 3.68053 .953 −8.0280 14.3613
6 −11.00000 3.68053 .056 −22.1947 .1947
2 1 78.00000 * 3.68053 .000 66.8053 89.1947
3 73.83333 * 3.68053 .000 62.6387 85.0280
4 72.50000 * 3.68053 .000 61.3053 83.6947
5 81.16667 * 3.68053 .000 69.9720 92.3613
6 67.00000 * 3.68053 .000 55.8053 78.1947
3 1 4.16667 3.68053 .864 −7.0280 15.3613
2 −73.83333 * 3.68053 .000 −85.0280 −62.6387
4 −1.33333 3.68053 .999 −12.5280 9.8613
5 7.33333 3.68053 .370 −3.8613 18.5280
6 −6.83333 3.68053 .447 −18.0280 4.3613
4 1 5.50000 3.68053 .670 −5.6947 16.6947
2 −72.50000 * 3.68053 .000 −83.6947 −61.3053
3 1.33333 3.68053 .999 −9.8613 12.5280
5 8.66667 3.68053 .205 −2.5280 19.8613
6 −5.50000 3.68053 .670 −16.6947 5.6947
5 1 −3.16667 3.68053 .953 −14.3613 8.0280
2 −81.16667 * 3.68053 .000 −92.3613 −69.9720
3 −7.33333 3.68053 .370 −18.5280 3.8613
4 −8.66667 3.68053 .205 −19.8613 2.5280
6 −14.16667 * 3.68053 .007 −25.3613 −2.9720
6 1 11.00000 3.68053 .056 -.1947 22.1947
2 −67.00000 * 3.68053 .000 −78.1947 −55.8053
3 6.83333 3.68053 .447 −4.3613 18.0280
4 5.50000 3.68053 .670 −5.6947 16.6947
5 14.16667 * 3.68053 .007 2.9720 25.3613
VAR00001
Tukey HSD
* The mean difference is significant at the 0.05 level.
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